Dr. Gaur was lead investigator for a Gilead clinical trial and subsequent drug approval for Biktarvy.® The study evaluated Biktarvy for efficacy and safety in virologically suppressed adolescents and children at least 6 years of age who are living with HIV. Through 48 weeks, the drug maintained high rates of virologic suppression with a low incidence of study-drug related adverse events and no treatment-emergent resistance. Biktarvy is indicated in the U.S. as a complete regiment for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history.

Dr. Gaur attended UT, College of Graduate Health Sciences in Memphis, TN. Additionally, he received his MBBS as well as MD and DCH from South Gujarat University, Surat, Gujarat, India.

His clinical interests include:

Diagnosis and treatment of infections in immunocompromised children

Pediatric HIV infection

Epidemiology of infectious disease

Source: www.stjude.org

Pin It on Pinterest